Founded in 2017, EpiDestiny combines state-of-the-art research and capabilities to expand the “proof of principle” clinical studies. This allows us to advance the target discovery in our laboratory to treating patients in clinical trials at an accelerated pace. We are investigating many of the largest and most lethal cancers through our proprietary platforms that identify and validate novel gene control targets.
EpiDestiny has 2 investigational drugs in human clinical trials. As single agents, 2 have generated objective clinical responses in patients with myelofibrosis, AML/MDS, and non-small cell lung cancer. We plan to initiate phase 2/3 clinical trials in 2018. Beyond these 2 clinical programs, we have a pipeline of additional novel targets to address other major cancer types.
Why are we testing EPI01, for clinical use in Cancer Immunotherapy, Cancer Cell Differentiation?
What did the Researchers Do and Find?
What do these Findings Mean?